论文部分内容阅读
目的分析单药多西紫杉醇(泰素帝)治疗非小细胞肺癌剂量强度与疗效和毒性的关系。方法将63例晚期非小细胞肺癌患者随机分为A组21例、B组27例、C组15例,分别给予单药泰素帝60 mg/m2、75 mg/m2、100mg/m2,评估泰素帝剂量强度与疗效及毒性的关系。结果A、B、C 3组的PR率分别为19%,30%,40%,中位生存时间分别为7.9个月、11.4个月和12.9个月。B组和C组PR率和生存期明显高于A组(P<0.05),B组和C组比较无显著性差异(P>0.05)。C组毒副作用发生率明显高于A组和B组(P<0.05),A组和B组比较无显著性差异(P<0.05)。结论单药泰素帝治疗非小细胞肺癌患者时,选用75 mg/m2剂量是疗效和毒副作用的最佳结合点。
Objective To analyze the relationship between the dose intensity of single-agent docetaxel (Taxotere) and efficacy and toxicity in the treatment of non-small cell lung cancer. Methods Sixty-three patients with advanced non-small cell lung cancer were randomly divided into group A (n = 21), group B (n = 27) and group C (n = 15) Relationship between dose intensity and efficacy and toxicity of Taxotere Results The PR rates in groups A, B and C were 19%, 30% and 40%, respectively. The median survival time was 7.9 months, 11.4 months and 12.9 months respectively. The PR rate and survival rate in group B and group C were significantly higher than those in group A (P <0.05). There was no significant difference between group B and group C (P> 0.05). The incidence of side effects in group C was significantly higher than that in group A and group B (P <0.05). There was no significant difference between group A and group B (P <0.05). Conclusion The single-agent taxotere treatment of non-small cell lung cancer patients, the choice of 75 mg / m2 dose is the best combination of efficacy and side effects.